Anika Therapeutics Pain Management Sales Offset COVID Surgical Declines

Anika Therapeutics reported 3Q21 orthopedic sales of $37.3 million, +23.9% vs. 3Q20. The company revised its full-year 2021 guidance to overall growth in the range of +9% to +11% over 2020, down from a previous range of +11% to +14%. Anika expects mid single-digit growth in its orthobiologics franchise and high teen growth in its joint...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us